Latest Surgical oncology Stories
Power morcellators first came to market decades ago, under the FDA’s 510(k) clearance program, which in most cases does not require controlled human testing. New
Growing body of clinical evidence shows greater penetration, targeted delivery, efficiency and cost savings with the SIS WESTMINSTER, Colo., Dec.
- Late-Breaking Data From Pilot Study on New Electromagnetic Wave Device For Tissue Targeting During Breast Conservation Surgery at San Antonio Breast Cancer Symposium - SAN ANTONIO,
Research Shows Promise in Reducing Complications of Gastrointestinal Surgery COLUMBIA, Md., Dec. 9, 2014 /PRNewswire/ -- ACell, Inc.
AMSTERDAM, December 9, 2014 /PRNewswire/ -- ~ Data confirms the potential of ATIR(TM) in partially matched hematopoietic stem cell transplants ~ Kiadis Pharma
The doctor who is spearheading a petition to ban power morcellators says the FDA’s most recent warning is not enough to protect hysterectomy and fibroid removal patients from the risk of spreading
Posters Include an Epidemiological Measure of the Effectiveness Analysis of Defibrotide from a Phase 3 Trial in Severe Hepatic VOD, as well as Updates from an International Compassionate Use Program
HCA is just the latest healthcare provider to reassess the use of power morcellators in light of their potential to spread undetected uterine cancers. New York,
Reconstructive surgery is final step in battling breast cancer - but what of the women who can't afford it? My Hope Chest offered hope at the Fort Harrison this past week. CLEARWATER,